CSV October 21, 2023 through October 21, 2025 All Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
SODIUM NITR	*Identification*	*USP39–NF34*	5880	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First*	Line 1 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
OPRUSSIDE							*Supplement to USP40–NF35*	*Identification C*: Change A solution (1 in 4) responds to the flame test for *Sodium* <191>. to: A solution (1 in 4) imparts an intense yellow color to a nonluminous flame.
TRIHEXYPHENIDYL HYDROCHLORIDE EXTENDED-RELEASE CAPSULES	*Assay*	*USP39–NF34*	6265	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 1 of *Mobile phase* and *Chromatographic system*: Change Prepare as directed in the *Assay* under *Trihexyphenidyl Hydrochloride*. to: *Mobile phase*—Prepare a mixture of acetonitrile, water, and triethylamine

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								(920:80:0.2), adjust with phosphoric acid to a pH of 4.0, mix, filter, and degas. Make adjustments if necessary (see *System Suitability* under *Chromatography* <621>). *Chromatographic system* (see *Chromatography* <621>)—The liquid chromatograph is equipped with a 210-nm detector and a 4.6-mm × 8-cm column that contains 3-µm packing L1. The flow rate is about 2 mL per minute. Chromatograph the *Standard preparation*,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								and record the peak responses as directed for *Procedure*: the column efficiency determined from the analyte peak is not less than 1300 theoretical plates, the tailing factor for the analyte peak is not more than 3.0, and the relative standard deviation for replicate injections is not more than 1.0%. AND Line 1 of *Procedure*: Change Proceed as directed for *Procedure* in the *Assay* under

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Trihexyphenidyl Hydrochloride. to: Separately inject equal volumes (about 10 µL) of the *Standard preparation* and the *Assay preparation* into the chromatograph, record the chromatograms, and measure the responses for the major peaks. AND Line 6 of *Procedure*: Change and the other terms are as defined therein. to: *C* is the concentration, in mg per mL, of USP

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Trihexyphenidyl Hydrochloride RS in the *Standard preparation*, r_U and r_S are the trihexyphenidyl peak responses obtained from the *Assay preparation* and the *Standard preparation*, respectively.
TRIHEXYPHENIDYL HYDROCHLORIDE ORAL SOLUTION	*Assay*	*USP39–NF34*	6266	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 1 of *Mobile phase* and *Chromatographic system*: Change Prepare as directed in the *Assay* under *Trihexyphenidyl Hydrochloride*. to: *Mobile phase*—Prepare a mixture of acetonitrile, water, and triethylamine

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								(920:80:0.2), adjust with phosphoric acid to a pH of 4.0, mix, filter, and degas. Make adjustments if necessary (see *System Suitability* under *Chromatography* <621>). *Chromatographic system* (see *Chromatography* <621>)—The liquid chromatograph is equipped with a 210-nm detector and a 4.6-mm × 8-cm column that contains 3-µm packing L1. The flow rate is about 2 mL per minute. Chromatograph the *Standard preparation*,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								and record the peak responses as directed for *Procedure*: the column efficiency determined from the analyte peak is not less than 1300 theoretical plates, the tailing factor for the analyte peak is not more than 3.0, and the relative standard deviation for replicate injections is not more than 1.0%. AND Line 1 of *Procedure*: Change Proceed as directed for *Procedure* in the *Assay* under

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Trihexyphenidyl Hydrochloride. to: Separately inject equal volumes (about 10 µL) of the *Standard preparation* and the *Assay preparation* into the chromatograph, record the chromatograms, and measure the responses for the major peaks. AND Line 7 of *Procedure*: Change and the other terms are as defined therein. to: *C* is the concentration, in mg per mL, of USP

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Trihexyphenidyl Hydrochloride RS in the *Standard preparation*, r_U and r_S are the trihexyphenidyl peak responses obtained from the *Assay preparation* and the *Standard preparation*, respectively.
BANABA LEAF DRY EXTRACT	IDENTIFICATION	*USP39–NF34*	6494	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Delete *Identification A*. AND Line 1 of *Identification B*: Change *B.* to: *A.* AND Line 1 of *Identification C*: Change *C.* to: *B.*
FUMARIC ACID	SPECIFIC	*USP39–NF34*	7309	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First*	Line 1: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	TESTS/*Water Determination, Method I <921>*						*Supplement to USP40–NF35*	0.5% to: NMT 0.5%
BISOCTRIZOLE	IM PURITIES/*Organic Impurities*	*First Supplement to USP39–NF34*	8008	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Footnote b of *Table 2*: Change Phenol, 2,2-methyle nebis[6-(2*H*-benzotriazol-2-yl)-4-(1,1,3,3-tetramethylbutyl)]. to: Phenol, 2,2?-m*H*-benzotriazol-2-yl)-4-(1,1,3,3-tetramethylbutyl)].
BISOCTRIZOLE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*First Supplement to USP39–NF34*	8008	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 2 of USP Bisoctrizole Resolution Mixture RS: Change A mixture of approximately 1.5% of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								bisoctrizole isomer [phenol, 2,2-methylenebis[6-(2*H*-benzotriazol-2-yl)-4-(1,1,3,3-tetramethylbutyl)]] in a matrix of bisoctrizole. to: A mixture of approximately 1.5% of bisoctrizole isomer [phenol, 2,2?-methylene bis[6-(2*H*-benzotriazol-2-yl)-4-(1,1,3,3-tetramethylbutyl)]] in a matrix of bisoctrizole.
SULINDAC TABLETS	IM PURITIES/*Organic Impurities*	*First Supplement to USP39–NF34*	8160	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 1 of *System suitability*/*Relative standard deviation*: Change NMT 2.0% for any peak

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: NMT 2.0% for sulindac, sulindac related compound B, and sulindac related compound C AND Line 3 of *Analysis*: Change Calculate the percentage of the labeled amount of sulindac related compound A, sulindac related compound B, or sulindac related compound C in the portion of Tablets taken: to: Calculate the percentage of sulindac related compound B or sulindac related compound C in

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								the portion of Tablets taken: AND Line 8 of *Analysis*: Change r_U = peak response of sulindac related compound A, sulindac related compound B, or sulindac related compound C from the *Sample solution* to: r_U = peak response of sulindac related compound B or sulindac related compound C from the *Sample solution* AND Line 12 of *Analysis*: Change r_S = peak response of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								sulindac related compound A, sulindac related compound B, or sulindac related compound C from the *Standard solution* to: r_S = peak response of sulindac related compound B or sulindac related compound C from the *Standard solution*
OMEGA-3-ACID ETHYL ESTERS CAPSULES	ASSAY/*Content of EPAee, DHAee, and Total Omega-3-Acid Ethyl Esters/Analysis*	*Second Supplement to USP39–NF34*	8755	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 16 of the third equation: Change *L* = label claim of total omega-3-acids ethyl esters (g/Capsule) to: *L* = label claim of total omega-3-acids

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								ethyl esters (mg/Capsule)
NAPROXEN SODIUM TABLETS	IMPURITIES/*Organic Impurities*	*Second Supplement to USP39–NF34*	Online	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 6 of *Analysis*: Change Result = $(r_U/r_S) \times (C_U/C_S) \times 100$ to: Result = $(r_U/r_S) \times (C_S/C_U) \times 100$
SEMISOLID DRUG PRODUCTS—PERFORMANCE TESTS	IN VITRO PERFORMANCE TESTS	*USP39–NF34*	1869	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 7 of *Application of Drug Release*: Change The individual amounts of drug released from *R* is plotted versus time, to: The individual amounts of drug released from *R* are plotted versus the square root of time,
REAGENTS, INDICATORS AND SOLUTIONS	REAGENTS/*6. General Tests for Reagents*/*6.2*	*USP39–NF34*	2080	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	In the numerator of the equation: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	Amino Nitrogen Test in Reagents							2.8 to: 14 AND Add × *f* AND Line 10: Change where %LOD is the percentage of loss on drying. to: where *f* is the correction factor obtained in the standardization of 0.2 N sodium hydroxide and %LOD is the percentage of loss on drying.
ALPRAZOLAM EXTENDED-RELEASE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>*	*USP39–NF34*	2389	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Variable definition list of second equation in *Test 2/Analysis*: Change V_S = volume of the *Sample*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution withdrawn at each time point and replaced with *Medium* (mL) to: V_S = volume of the *Sample solution* withdrawn at each time point (mL) AND Variable definition list of second equation in *Test 3*/*Analysis*: Change V_S = volume of the *Sample solution* withdrawn at each time point and replaced with *Medium* (mL) to: V_S = volume of the *Sample*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution withdrawn at each time point (mL)
BACITRACIN ZINC	IMPURITIES	*USP39–NF34*	2674	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Delete the *Residue on Ignition <281>* test.
DIAZEPAM INJECTION	*Assay*	*USP39–NF34*	3445	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 7 of *Procedure*: 50C / $V(R_U / R_S)$ to: $50(C / V)(R_U / R_S)$
DICLOFENAC SODIUM EXTENDED-RELEASE TABLETS	IMPURITIES/*Organic Impurities*	*USP39–NF34*	3460	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 1 of *Standard solution*: Change 0.001 mg/mL of USP Diclofenac Sodium RS in *Diluent* to: 0.001 mg/mL each of USP Diclofenac Sodium RS and USP Diclofenac Related Compound A RS in *Diluent*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
IMIQUIMOD CREAM	IMPURITIES/*Organic Impurities*	*USP39–NF34*	4289	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Row 2 of Column 3 of *Table 2*: Change 1.5 to: 1.15 AND Row 3 of Column 3 of *Table 2*: Change 1.15 to: 1.5
LORAZEPAM	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP39–NF34*	4618	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 3 of USP Lorazepam Related Compound B RS: Change $C_{13}H_9ClNO$ to: $C_{13}H_9Cl_2NO$
LORAZEPAM INJECTION	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP39–NF34*	4620	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 3 of Lorazepam Related Compound B RS: Change $C_{13}H_9ClNO$ to: C

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								$^{13}H_9Cl_2NO$

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
LORAZEPAM ORAL CONCENTRATE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP39–NF34*	4621	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 3 of Lorazepam Related Compound B RS: Change $C_{13}H_9ClNO$ to: $C_{13}H_9Cl_2NO$
LORAZEPAM TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference Standards RS <11>*	*USP39–NF34*	4622	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 3 of USP Lorazepam Related Compound B RS: Change $C_{13}H_9ClNO$ to: $C_{13}H_9Cl_2NO$
METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS	PERFORMANCE TESTS/*Dissolution <711>*	*USP39–NF34*	4766	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 3 of *Test 3*: Change *Medium, Apparatus 1, Apparatus 2*, and *Analysis*: to: *Medium, Apparatus 1*, and *Apparatus 2*:
MYCOPHENOLATE SODIUM	ASSAY/*Procedure*	*USP39–NF34*	4965	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 3: Change *Solvent A* to: *Solution A*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								AND Line 5: Change *Solvent B* to: *Solution B*
NALTREXONE HYDROCHLORIDE	*Related compounds*	*USP39–NF34*	4985	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 5: Change $10F(C/W)(r_U / r_S)$ to: $1000F(C/W)(r_U/r_S)$
NICOTINE POLACRILEX	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP39–NF34*	5061	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Add USP Polacrilex Resin RS
OXANDROLONE TABLETS	*Dissolution <711>/Test 3*	*USP39–NF34*	5193	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 3 of *Chromatographic system*: Change 30-cm column to: 3-cm column
PALIPERIDONE	CHEMICAL INFORMATION	*USP39–NF34*	5253	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 5: Change (9*RS*)-3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl]]ethyl]-9-hydroxy-2-methyl-6,7,8,9-tetrah

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								ydro-4*H*-pyrido [1,2-*a*]pyrimidin-4-one to: (9*RS*)-3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl]]ethyl]-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4*H* -pyri do[1,2-*a*]pyrimidin-4-one
PALIPERIDONE	IMPURITIES/*Organic Impurities*/*System suitability*/*Suitability requirements*	*USP39–NF34*	5253	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 3 of *Resolution*: Change hydroxybenzyl to: hydroxybenzoyl
RANITIDINE INJECTION	*USP Reference standards <11>*	*USP39–NF34*	5670	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 2 of USP Ranitidine Related Compound C RS: Change *N* -[2-[[[5-[(Dimethylamino)methyl]

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								-2-furanyl]methyl] sulfinyl]ethyl]-*N*-methyl-2-nitro-1,1-ethenediamine. to: *N*-{2-[({5-[(Dimethylamino)methyl]-2-furanyl}meth
RANITIDINE ORAL SOLUTION	*USP Reference standards <11>*	*USP39–NF34*	5671	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	*N*?-methyl-2-nitro-1,1-ethenediamine. Line 2 of USP Ranitidine Related Compound C RS: Change *N*-[2-[[[5-[(Dimethylamino)methyl]-2-furanyl]methyl] su

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								lfinyl]ethyl]-*N* -methyl-2-nitro-1,1-ethenediamine. to: *N* -{2-[({5-[(Dimethylamino)methyl]-2-furanyl}meth
RANITIDINE TABLETS	*USP Reference standards <11>*	*USP39–NF34*	5672	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	*N* ?-methyl-2-nitro-1,1-ethenediamine. Line 2 of USP Ranitidine Related Compound C RS: Change *N* -[2-[[[5-[(Dimethylamino)methyl]-2-furanyl]methyl] su lfinyl]ethyl]-*N* -methyl-2-nitro-

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								1,1-ethenediamine. to: *N* -{2-[({5-[(Dimethylamino)methyl]-2-furanyl}meth
RANITIDINE IN SODIUM CHLORIDE INJECTION	*USP Reference standards <11>*	*USP39–NF34*	5673	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	*N* ?-methyl-2-nitro-1,1-ethenediamine. Line 2 of USP Ranitidine Related Compound C RS: Change *N* -[2-[[[5-[(Dimethylamino)methyl]-2-furanyl]methyl] su lfinyl]ethyl]-*N* -methyl-2-nitro-1,1-ethenediamine. to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								N -{2-[({5-[(Dimethylamino)methyl]-2-furanyl}meth
								N ?-methyl-2-nitro-1,1-ethenediamine.
SAMARIUM Sm 153 LEXIDRONAM INJECTION	*Other requirements*	*USP39–NF34*	5791	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 1: Change *Injections and Implanted Drug Products <1>*; not subject to *Container Content*. to: Meets the requirements of *Injections and Implanted Drug Products <1>*; not subject to *Container content*.
TETRACYCLINE HYDROCHLORIDE CAPSULES	ASSAY/ *Procedure*	*USP39–NF34*	6082	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 6 of *Sample solution*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								dilute with *Diluent* to volume. to: dilute with *Solution A* to volume.
TROSPIUM CHLORIDE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP39–NF34*	6287	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 3 of USP Trospium Chloride Related Compound C RS:Change (1*R*,3*r*,5*S*)-3-Hydroxyspiro[8-azoniabicyclo[3.2.1]octane-8,1?-pyrrolidinium] chloride. to: (1*R*,3*r*,5*S*)-3-Hydroxyspiro[8-azoniabicyclo[3.2.1]octane-8,1?-pyrrolidinium] chloride, or (1*R*,3*r*,5*S*)-3-Hydroxyspiro[bicyclo[3.2.1]octane-8,1?-pyrrolidin]-1?-ium

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								chloride.
CHONDROITIN SULFATE SODIUM, SHARK	IMPURITIES/*Limit of Protein*	*USP39–NF34*	6570	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 2 of *Instrumental conditions*: Change (See *Spectrophotometry and Light-Scattering <851>*.) to: (See *Ultraviolet-Visible Spectroscopy <857>*.)
CHONDROITIN SULFATE SODIUM, SHARK	SPECIFIC TESTS/*Clarity and Color of Solution*	*USP39–NF34*	6570	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 2 of *Instrumental conditions*: Change (See *Spectrophotometry and Light-Scattering <851>*.) to: (See *Ultraviolet-Visible Spectroscopy <857>*.)
CHONDROITIN SULFATE	COMPOSITION/*Disaccharide*	*USP39–NF34*	6570	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 2 of *Chondroitinase*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
SODIUM, SHARK	*Composition*							*ABC solution*: Change 10.0 mL of *Buffer solution* to: 1.0 mL of *Buffer solution* AND Line 4 of *Analysis*: Change and 1.0 mL to: and 0.1 mL
VINPOCETINE	IM PUR ITIES/*Organic Impurities*	*USP39–NF34*	6880	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Footnote a of *Table 1*: Change Ethyl (12*RS*,13a*SR*,13b*SR*)-13a-ethyl-12-hydroxy-2,3,5,6,12,13,13a,13b-octahydro-1*H*-indolo[3,2,1-*de*]pyrido[3,2,1-*ij*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								][1,5]naphthyridine-12-carboxylate (ethyl vincaminate). to: Ethyl (12*S*,13a*S*,13b*S*)-13a-ethyl-12-hydroxy-2,3,5,6,12,13,13a,1
								H-indolo[3,2,1-*de*]pyrido[3,2,1-*ij*][1,5]naphthyridine-12-carboxylate (ethyl vincaminate). AND Footnoteb of *Table 1*: Change Methyl (13a*S*,13b*S*)-13a-ethyl-9-m

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								ethoxy-2,3,5,6,13a,13b-hexahydro-1*H*-indolo[3,2,1-*de*]pyrido[3,2,1-ij][1,5]naphthyridine-12-carboxylate (apovincamine). to: Methyl (13a*S*,13b*S*)-13a-ethyl-2,3,5,6,13a,13b-hexahydro-1*H*-indolo[3,2,1-*de*]pyrido[3,2,1-*ij*][1,5]naphthyridine-12-carboxylate (apovincamine).

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								AND Footnote d of *Table 1*: Change Ethyl (12*RS*,13a*RS*,13b*RS*)-13a-ethyl-2,3,5,6,12,13,13a,13b-octahydro-1*H*-indolo[3,2,1-*de*]pyrido[3,2,1-*ij*][1,5]naphthyridine-12-carboxylate (dihydrovinpocetine). to: Ethyl (12*R*,13a*S*,13b*S*)-13a-ethyl-2,3,5,6,12,13,13a,13b-octahydro-1*H*-indolo[

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								3,2,1-*de*]py rido[3 ,2,1-*ij*][1,5]naphthyridi ne-12-carboxyla te (dihydrovinpo cetine).
CETYL ALCOHOL	IM PURITIES/*Limit of Related Fatty Alcohols*	*USP39–NF34*	7239	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 1 of *Sample solution*: Change 1 mg/mL of Cetyl Alcohol in ethanol to: Prepare 1.0 mg/mL of Cetyl Alcohol in ethanol, and heat the solution in a sealed container in a 50° water bath until cetyl alcohol is dissolved. Allow the solution to cool to room temperature,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
MYRISTYL ALCOHOL	ASSAY/ *Procedure*	*USP39–NF34*	7413	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	and mix well. Line 1 of *Standard solution*: Change Prepare 1.0 mg/mL of USP Myristyl Alcohol RS in *Internal standard solution*, and heat the solution in a sealed container in a 50° water bath until myristyl alcohol is dissolved. Allow the solution to cool to room temperature, and mix well. to: 1.0 mg/mL of USP Myristyl Alcohol RS in *Internal standard solution* AND

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Line 1 of *Sample solution*: Change Prepare 1.0 mg/mL of Myristyl Alcohol in *Internal standard solution*, and heat the solution in a sealed container in a 50° water bath until myristyl alcohol is dissolved. Allow the solution to cool to room temperature, and mix well. to: 1.0 mg/mL of Myristyl Alcohol in *Internal standard solution*
OLEYL ALCOHOL	ASSAY/ *Procedure*	*USP39–NF34*	7424	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 1 of *Standard solution*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Change Prepare 1.0 mg/mL of USP Oleyl Alcohol RS in *Internal standard solution*, and heat the solution in a sealed container in a 50° water bath until oleyl alcohol is dissolved. Allow the solution to cool to room temperature, and mix well. to: 1.0 mg/mL of USP Oleyl Alcohol RS in *Internal standard solution* AND Line 1 of *Sample solution*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Prepare 1.0 mg/mL of Oleyl Alcohol in *Internal standard solution*, and heat the solution in a sealed container in a 50° water bath until oleyl alcohol is dissolved. Allow the solution to cool to room temperature, and mix well. to: 1.0 mg/mL of Oleyl Alcohol in *Internal standard solution*
SODIUM CETO STEARYL SULFATE	IM PURITIES/*Limit of Sodium Chloride and Sodium Sulfate*/*Sodium sulfate*/	*USP39–NF34*	7518	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 1 of *Endpoint detection*: Change Potentiometric to: Visual

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	Titrimetric system							
HAZARDOUS DRUGS—HANDLING IN HEALTHCARE SETTINGS	5. FACILITIES AND ENGINEERING CONTROLS/*5.3 Compounding*	*First Supplement to USP39–NF34*	7721	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	First bullet in second paragraph: Change • Be externally vented through high-efficiency particulate air (HEPA) filtration to: • Be externally vented
PAROXETINE EXTENDED-RELEASE TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*First Supplement to USP39–NF34*	8121	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	USP Paroxetine Related Compound B RS: Add $C_{19}H_{21}NO_3 \cdot HCl$ 347.84
CONTAINERS--PERFORMANCE TESTING	MOISTURE VAPOR TRANSMISSION/*Packaging System Classification for Multiple-Unit Containers and Unit-Dose Containers for*	*USP38–NF33*	465	25-Mar-2016	1-Apr-2016	*USP40–NF35*	*USP40–NF35*	Line 1 of the Equation: Change $[(W_{1i} ? W_T) ? (W_{14i} ? W_T) ? (W_{C1} ? W_{C14})] \times 365 \times \{[100/(W_{1i} ? W_T)] \times 14\}$ to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	Liquid Oral Dosage Forms/ Procedure							[(W1i? W_T) ? (W_{14i} ? W_T) ? (W_{C1} ? W_{C14})] × 365 × 100/(W_{1i} ? W_T) × 14
ARGININE HYDROCHLORIDE	SPECIFIC TESTS/*Chloride Content*	*USP38–NF33*	2279	25-Mar-2016	1-Apr-2016	*USP40–NF35*	*USP40–NF35*	Delete the subsection *Blank*: 140 mL of water and 1 mL of dichlorofluorescein TS AND The equation in the *Analysis*: Change Result = [(*V* ? *B*) × *N* × *F* × 100]/*W* to: Result = (*V* × *N* × *F* × 100)/*W* AND Line 10 of *Analysis*: Delete *B* = *Blank* titrant volume (mL)
SELENOMETHIONINE	CHEMICAL INFORMATION	*USP38–NF33*	6226	25-Mar-2016	1-Apr-2016	*USP40–NF35*	*USP40–NF35*	Line 3: Change [1464-42-2] to: [3211-76-5]
RESIDUAL	4. HCP IMMUN	*Second*	7647	25-Mar-2016	1-Apr-2016	*USP40–NF35*	*USP40–NF35*	*Product* column:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
HOST CELL PROTEIN MEASUREMENT IN BIOPHARMACEUTICALS	OASSAY METHOD V ALIDATION/*4.3 Sample Linearity/Table 4*	*Supplement to USP38–NF33*						Change 10.00 (neat), 5.00, 2.50, 1.25, 0.63, 0.31, 0.16 to: 10.00 (neat), 5.00, 2.50, 1.25, 0.625, 0.3125, 0.15625 AND *Sample 1/HCP ratio* column: Change 4.9, 5.7, 4.8, 5.9, 5.0, 5.1, <6 to: 4.90, 5.70, 4.80, 5.92, 4.96, 5.12, <6 AND *Sample 2/HCP ratio* column: Change 2.0, 3.3, 4.0, 5.9, 5.3, 6.1, <6 to: 2.00, 3.30, 4.00, 5.92, 5.28, 6.08, <6 AND *Sample 3/HCP*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								ratio column: Change 0.3, 0.5, 0.6, 0.9, 1.4, <6, <6 to: 0.32, 0.50, 0.60, 0.88, 1.44, <6, <6 AND *Sample 3/% max ratio value* column: Change 83% to: 61%
PLASTIC MATERIALS OF CONSTRUCTION	SPECIFICATIONS/ *Polyethylene/Extractable Metals*	*USP39–NF34*	493	25-Mar-2016	1-Apr-2016	*USP40–NF35*	*USP40–NF35*	Line 1 of *Zirconium*: Change 1 µg/g. to: 0.1 µg/g.

Pagination

- First page « First
- Previous page ‹ Previous
- …
- Page 22
- Page 23
- Page 24

- Page 25
- Page 26
- Page 27
- Page 28
- Page 29
- Page 30
- …
- Next page Next ›
- Last page Last »